BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2394511)

  • 1. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
    Ferroni P; Szpak C; Greiner JW; Simpson JF; Guadagni F; Johnston WW; Colcher D
    Int J Cancer; 1990 Sep; 46(3):445-51. PubMed ID: 2394511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoradiometric assay of CA 125 in effusions. Comparison with carcinoembryonic antigen.
    Pinto MM; Bernstein LH; Brogan DA; Criscuolo E
    Cancer; 1987 Jan; 59(2):218-22. PubMed ID: 3467816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
    Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
    Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated antigens in effusions of malignant and benign origin.
    Ammon A; Eiffert H; Reil S; Beyer JH; Droese M; Hiddemann W
    Clin Investig; 1993 Jun; 71(6):437-44. PubMed ID: 8353402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
    Klech H; Rona G; Hutter C; Bayer PM; Kummer F
    Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour associated antigens in diagnosis of serous effusions.
    Mezger J; Permanetter W; Gerbes AL; Wilmanns W; Lamerz R
    J Clin Pathol; 1988 Jun; 41(6):633-43. PubMed ID: 2454957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer.
    Kandylis K; Vassilomanolakis M; Baziotis N; Papadimitriou A; Tsoussis S; Ferderigou A; Efremidis AP
    Ann Oncol; 1990 Nov; 1(6):435-8. PubMed ID: 2083187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Lung Cancer; 2003 Jun; 40(3):289-94. PubMed ID: 12781427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA and CA 549 in serum and pleural fluid of patients with pleural effusion.
    Hernández L; Espasa A; Fernández C; Candela A; Martín C; Romero S
    Lung Cancer; 2002 Apr; 36(1):83-9. PubMed ID: 11891038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
    Wang XF; Wu YH; Wang MS; Wang YS
    Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
    Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
    Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic efficiency of carcinoembryonic antigen and CA125 in the cytological evaluation of effusions.
    Pinto MM; Bernstein LH; Rudolph RA; Brogan DA; Rosman M
    Arch Pathol Lab Med; 1992 Jun; 116(6):626-31. PubMed ID: 1616424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.
    Alataş F; Alataş O; Metintaş M; Colak O; Harmanci E; Demir S
    Lung Cancer; 2001 Jan; 31(1):9-16. PubMed ID: 11162861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
    Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
    Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions.
    Trapé J; Molina R; Sant F
    Tumour Biol; 2004; 25(5-6):276-81. PubMed ID: 15627892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites.
    De Wit R; Hoek FJ; Bakker PJ; Veenhof CH
    J Intern Med; 1991 May; 229(5):463-6. PubMed ID: 2040873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor markers in the diagnosis of malignant serous effusions.
    Cascinu S; Del Ferro E; Barbanti I; Ligi M; Fedeli A; Catalano G
    Am J Clin Oncol; 1997 Jun; 20(3):247-50. PubMed ID: 9167746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.
    Salama G; Miédougé M; Rouzaud P; Mauduyt MA; Pujazon MC; Vincent C; Carles P; Serre G
    Br J Cancer; 1998; 77(3):472-6. PubMed ID: 9472646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor markers in pleural effusion diagnosis.
    Tamura S; Nishigaki T; Moriwaki Y; Fujioka H; Nakano T; Fujii J; Yamamoto T; Nabeshima K; Hada T; Higashino K
    Cancer; 1988 Jan; 61(2):298-302. PubMed ID: 3275487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.